Exploration of hierarchical immune-related adverse events management system

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2400091062

Enrollment

Unknown

Registered

2024-10-20

Start date

2024-10-23

Completion date

Unknown

Last updated

2024-10-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

malignant tumor

Interventions

Case series:None

Eligibility

Sex/Gender

All

Age

18 Years to 85 Years

Inclusion criteria

Inclusion criteria: (1) The patient's age is = 85 years old. (2) Malignant tumor patients receiving treatment with immune checkpoint inhibitors (ICIs). (3) Can cooperate to complete various assessments and complete ICIs related toxicity management in the oncology department of Fuxing Hospital or community health medical institutions. (4) All participants sign informed consent.

Exclusion criteria

Exclusion criteria: (1) Patients with severe heart disease, such as acute myocarditis, acute myocardial infarction, acute heart failure, and Atrioventricular block, etc. (2) Merge and clarify patients with moderate to severe chronic obstructive pulmonary disease, interstitial lung disease, and other chronic lung diseases. (3) Pregnant women. (4) The baseline, in treatment, and post-treatment data are incomplete.

Design outcomes

Primary

Measure	Time frame
Developping;Creating a service model of tiered medical services for ICIs related toxicity management;	—

Secondary

Measure	Time frame
Severe irAE predictive biomarkers;	—

Countries

China

Contacts

Public ContactHua Fang

Fu Xing Hospital, Capital Medical University

laifu0130@sian.com+86 136 6120 2169

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026